NeuroSense Therapeutics(NRSN) - 2024 Q4 - Annual Report

Exhibit 99.1 NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates CAMBRIDGE, Mass., April 7, 2025 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update. Business highlights from 2024 and to date ● Key patent granted by U.S. Patent and Trademark Office ( ...